References
- Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005; 41: 27–8
- Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidaemia. Arch Intern Med 1989; 149: 2226–8
- Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of fungal endophthalmitis with voriconazole and caspofungin. Am J Opthalmol 2005; 139: 135–40
- Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 2005; 40: 446–8
- Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, Prince RA. Determination of vitreous, acqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122: 42–7
- Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004; 137: 820–5
- Sabbatani S, Manfredi R, Pavoni M, Consales A, Chiodo F. Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure. Mycopathologia 2004; 158: 165–71